We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » OPDP Warning and Untitled Letters Focus on Risk Omission, Minimization
OPDP Warning and Untitled Letters Focus on Risk Omission, Minimization
August 22, 2012
Some industry experts have suggested that FDA’s Office of Prescription Drug Promotion (OPDP), formerly the Division of Drug Marketing, Advertising and Communications (DDMAC), has slowed down its enforcement pace via warning letters.